161 related articles for article (PubMed ID: 9261526)
1. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.
Smyth JF; Bowman A; Perren T; Wilkinson P; Prescott RJ; Quinn KJ; Tedeschi M
Ann Oncol; 1997 Jun; 8(6):569-73. PubMed ID: 9261526
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
Cascinu S; Cordella L; Del Ferro E; Fronzoni M; Catalano G
J Clin Oncol; 1995 Jan; 13(1):26-32. PubMed ID: 7799029
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.
Di Re F; Bohm S; Oriana S; Spatti GB; Zunino F
Cancer Chemother Pharmacol; 1990; 25(5):355-60. PubMed ID: 2306797
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.
Locatelli MC; D'Antona A; Labianca R; Vinci M; Tedeschi M; Carcione R; Corbo A; Venturino P; Luporini G
Tumori; 1993 Feb; 79(1):37-9. PubMed ID: 8497920
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin.
Cassidy J; Paul J; Soukop M; Habeshaw T; Reed NS; Parkin D; Kaye SB
Cancer Chemother Pharmacol; 1998; 41(2):161-6. PubMed ID: 9443630
[TBL] [Abstract][Full Text] [Related]
6. Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
van Rijswijk RE; Hoekman K; Burger CW; Verheijen RH; Vermorken JB
Ann Oncol; 1997 Dec; 8(12):1235-41. PubMed ID: 9496389
[TBL] [Abstract][Full Text] [Related]
7. A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma.
Bohm S; Battista Spatti G; Di Re F; Oriana S; Pilotti S; Tedeschi M; Tognella S; Zunino F
Anticancer Res; 1991; 11(4):1613-6. PubMed ID: 1746919
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer.
Passalacqua R; Cocconi G; Caminiti C; Silingardi V; Bella MA; Bichisao E; Michiara M; Malavasi V; Donati D; Di Costanzo F; Rocca A; Di Sarra S; Scaglione F; Fraschini F
J Clin Oncol; 1997 Jun; 15(6):2467-73. PubMed ID: 9196163
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
Cascinu S; Catalano V; Cordella L; Labianca R; Giordani P; Baldelli AM; Beretta GD; Ubiali E; Catalano G
J Clin Oncol; 2002 Aug; 20(16):3478-83. PubMed ID: 12177109
[TBL] [Abstract][Full Text] [Related]
11. Hepatotoxicity and pharmacokinetics of cisplatin in combination therapy with a traditional Chinese medicine compound of Zengmian Yiliu granules in ICR mice and SKOV-3-bearing nude mice.
Gong C; Qian L; Yang H; Ji LL; Wei H; Zhou WB; Qi C; Wang CH
BMC Complement Altern Med; 2015 Aug; 15():283. PubMed ID: 26283082
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.
Bolis G; Colombo N; Pecorelli S; Torri V; Marsoni S; Bonazzi C; Chiari S; Favalli G; Mangili G; Presti M
Ann Oncol; 1995 Nov; 6(9):887-93. PubMed ID: 8624291
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
[TBL] [Abstract][Full Text] [Related]
14. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma.
Böhm S; Oriana S; Spatti G; Di Re F; Breasciani G; Pirovano C; Grosso I; Martini C; Caraceni A; Pilotti S; Zunino F
Oncology; 1999; 57(2):115-20. PubMed ID: 10461057
[TBL] [Abstract][Full Text] [Related]
15. Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes.
Cadoni E; Valletta E; Caddeo G; Isaia F; Cabiddu MG; Vascellari S; Pivetta T
J Inorg Biochem; 2017 Aug; 173():126-133. PubMed ID: 28511063
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells.
Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T
Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239
[TBL] [Abstract][Full Text] [Related]
17. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
18. A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer.
Parnis FX; Coleman RE; Harper PG; Pickering D; Topham C; Whittington JR; Tedeschi M
Eur J Cancer; 1995 Sep; 31A(10):1721. PubMed ID: 7488438
[No Abstract] [Full Text] [Related]
19. Long-term evolution of renal function in patients with ovarian cancer after whole abdominal irradiation with or without preceding cisplatin.
Schneider DP; Marti HP; Von Briel C; Frey FJ; Greiner RH
Ann Oncol; 1999 Jun; 10(6):677-83. PubMed ID: 10442190
[TBL] [Abstract][Full Text] [Related]
20. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
